Synopsis: Divi’s Laboratories shares fell 4% after MSN won a U.S. patent case on Entresto, threatening up to 20% of Divi’s revenue. IIFL flagged a 12–13% EBITDA risk and maintained a “reduce” rating with a Rs 5,465 target, implying 20% downside. The shares...
Synopsis: Divis Laboratories’ share is in focus after leading brokerage HSBC has shown its bullish stance on the pharmaceutical company by raising its target price by a staggering 57 percent. The shares of this pharmaceutical company came under the spotlight of...
Search Topic or Keyword
Easiest Stock Screener Tool!
Best stock discovery tool with +130 filters, built for fundamental analysis. Profitability, Growth, Valuation, Liquidity, and many more filters. Search Stocks Industry-wise, Export Data For Offline Analysis, Customizable Filters.
